Navigation Links
Rigel Provides Pipeline Update
Date:10/24/2013

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced updates on two of the Company's pipeline products: R333, a topical dermatological JAK/SYK inhibitor, and fostamatinib, an oral SYK inhibitor.  

R333 Update
Rigel announced that R333, which was being evaluated as a potential therapeutic for active skin lesions in patients with discoid lupus erythematosus (DLE), did not meet the primary endpoint in a recently completed Phase 2 clinical study.  The primary endpoint was the proportion of patients who achieved at least a 50% decrease from baseline in the total combined Erythema and Scaling score of all treated lesions at Week 4.  R333 was shown to be relatively safe and well tolerated.  In light of these overall findings, Rigel has decided not to pursue this indication further with R333. 

Fostamatinib Update
Rigel representatives met with the FDA for an end-of-Phase 2 meeting for fostamatinib, an oral SYK inhibitor in development for patients with immune thrombocytopenic purpura (ITP).  Rigel expects to initiate two pivotal Phase 3 studies in the first half of 2014.  Each of these trials are expected to enroll approximately 75 patients who would be treated for six months and have the option to enroll in an extension study.  These trials will be randomized, placebo-controlled and will enroll verified ITP patients with platelet counts below 30,000 platelets per microliter of blood.   The goal of the trials will be to achieve a durable platelet count increase to over 50,000 platelets per microliter of blood.  Rigel expects top line data from these studies in 2015.

"These events provide clarity to Rigel's pipeline. We now have a clear picture of the Phase 3 program for fostamatinib in ITP and we p
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rigel to Present at Stifel Healthcare Conference
2. Rigel To Focus On ITP, DLE And Dry Eye
3. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
4. Rigel Announces Second Quarter 2013 Financial Results
5. Rigel Will Resume Responsibility for Fostamatinib Program
6. Rigels R348 to Initiate Phase 2 Clinical Trial in Dry Eye
7. Rigel Announces First Quarter 2013 Financial Results
8. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
9. Rigel Announces Participation at Two Investor Conferences
10. Rigel to Present at BIO CEO & Investor Conference
11. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... and NEW YORK, Sept. 6, 2011 Galenea ... collaboration to identify synaptic dysfunction linked to Huntington,s ... discovery platform.  Mounting evidence indicates that mutant huntingtin ... synaptic function, contributing to the behavioral, cognitive, and ...
... Sept. 6, 2011 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: ... leading domestic developer, manufacturer and marketer of orthopedic implants ... at the Company,s 2011 annual general meeting held in ... Specifically, the shareholders passed resolutions approving: , Re-election ...
Cached Medicine Technology:Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntington's Disease 2Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntington's Disease 3Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntington's Disease 4China Kanghui Holdings Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting 2
(Date:4/18/2014)... psychologists have made a brain-related discovery that could ... , This discovery opens up the possibility that ... a specific brain activity that the researchers have ... Journal of Neuroscience has just published ... an associate professor of psychology and his doctoral ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... chronic inflammation in benign prostate tissue was associated ... association was found even in those with low ... published in Cancer Epidemiology, Biomarkers & Prevention ... Cancer Research. , An analysis of prostate tissue ... arm of the Prostate Cancer Prevention Trial (PCPT) ...
(Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
(Date:4/17/2014)... One of the most popular vaccine brands for ... doctors may be overlooking some cost factors when choosing ... more expensive option, according to a new study by ... to administer can be driven by numerous factors," says ... a professor of computer science and of mathematics at ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2
... MIAMI, Sept. 11 Bupa,s ... a leading international healthcare company --,announced today the launch ... a deprived community in Ecuador where many families survive ... employees from around the globe will,travel to Ecuador until ...
... , DETROIT, Sept. 11 Blue Cross ... interim policy to automatically cover the cost of administration of the ... and individual coverage during the 2009-2010 flu season--unless a group chooses ... The Blues also announced that it will enable larger ...
... , , , ... magazine has ranked SoftLight Development, Inc. (SLD) NO. 643 on ... nation,s fastest-growing private companies. The list represents the most comprehensive ... entrepreneurs. Consumer electronics maker Vizio, Internet giant GoDaddy, rental car ...
... Sept. 11 During its 2009 Annual Conference in Washington, DC from ... some of the most pressing issues facing private care registries in the ... Conference include: , , , ... The program will cover PCA,s actions in the effort to ...
... , , , ... TD, pass completion , , CHICAGO, Sept. 11 ... Bears quarterback Jay Cutler means rooting for kids with diabetes. , ... Association (ADA) announced today they,re teaming up to help send children with ...
... , , , ... after bed bugs were believed to be exterminated nationwide, the teeny, ... proportions. , , They,re being spotted in ... motels, but posh resorts and upscale chains. In a recent study ...
Cached Medicine News:Health News:Bupa Launches its 2009 International Charity Challenge to Help a Rural Community in Ecuador 2Health News:Blue Cross Blue Shield of Michigan and Blue Care Network Announce Interim Policy to Cover H1N1 Vaccine Administration for Fully-Insured Groups During 2009-2010 Flu Season 2Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 2Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 3Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 4Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 5Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 6Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 7Health News:Private Care Association to Tackle Major Issues Impacting Home Care Industry 2Health News:Chicago Bears Quarterback Jay Cutler, Eli Lilly and Company and the American Diabetes Association Team Up to Fund Diabetes Camp Scholarships Through "Touchdowns for Diabetes" 2Health News:Chicago Bears Quarterback Jay Cutler, Eli Lilly and Company and the American Diabetes Association Team Up to Fund Diabetes Camp Scholarships Through "Touchdowns for Diabetes" 3Health News:Chicago Bears Quarterback Jay Cutler, Eli Lilly and Company and the American Diabetes Association Team Up to Fund Diabetes Camp Scholarships Through "Touchdowns for Diabetes" 4Health News:Rest Easy, the Safe, All-Natural Bed Bug Travel Spray 2
... unique combination of topography, auto-refraction and keratometer ... three devices. The compactness of this instrument ... perfect space and cost saving solution. ... examination time and easy handling makes working ...
... SP-3000 covers all needs regarding pachymetry in ... care., ,Compact design, colored touch-screen and "quick ... an "easy-to-use unit.,The wide measurement range from ... the possibility to measure very thin or ...
The PillCam™ ESO video capsule is specifically designed to view the inner lining of the Esophagus. The capsule is equipped with miniature cameras on both ends and is about the size of a multi-v...
... Wave combines three advanced technologies - ... easy-to-use refractive diagnostic workstation. Now, with ... refraction, corneal topography, optical path difference ... Wave allows you to evaluate your ...
Medicine Products: